Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that it has agreed to issue 376,175 New Ordinary Shares of 0.1p each (`New Ordinary Shares') at a price of 6.38p (the `Issue Price') to Hansard Communications Limited in respect of annual advisory fees. The Issue Price represents a discount of 1.85 per cent. to the closing share price of 6.5p as at 12 December 2011.
Admission and commencement of dealings in the New Ordinary Shares are expected to take place at 8.00 a.m. on 19 December 2011. There will be a total of 194,469,485 Ordinary Shares in issue following Admission of the New Ordinary Shares.
Scancell Holdings Plc
Dr Richard Goodfellow / Professor Lindy Durrant
+ 44 (0)207 245 1100*
Hansard (Financial PR)
Adam Reynolds/ Guy McDougall
+ 44 (0)207 245 1100
Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512
XCAP - Joint Broker
Jon Belliss/ Adrian Kirk
+44 (0)207 101 7070
*calls to this number will reach Hansard, at Scancell’s instruction.
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and entered clinical trials in 2010.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Mon, 20 May 2019 09:51:00
Sign up to our newsletter to stay up to date with Scancell